Michael Wyand D.V.M. Ph.D
Chief Executive Officer
Michael Wyand is a biopharmaceutical executive with over twenty-five years of experience leading life science companies. An accomplished leader, he has substantial experience managing R&D and serving as a corporate officer, effectively communicating strategy and value propositions to directors, investors, and partners.
As President/COO of Epirus Biopharmaceuticals (2012-2016), Michael managed a portfolio of biosimilar monoclonal antibodies through development and commercial stages with global partners. Previously, he led R&D at Percivia, a J&J/DSM joint venture, and BioAssets Development, which was acquired by Cephalon for $120M. At Therion Biologics, he spearheaded the development of PROSTVAC, a prostate cancer immunotherapeutic vaccine later licensed by Bristol-Myers Squibb for $975M, while also managing the design and construction of a cGMP manufacturing facility in Cambridge.
Michael began his career as President and CSO at Mason Laboratory, a Genzyme Transgenics subsidiary, where he served as Principal Investigator on a $7M NIAID AIDS vaccine contract. He trained in comparative pathology at Harvard Medical School after earning his DVM from Purdue University and his PhD in Pathology from the University of Connecticut. He also holds a BS in Biology from the University of Connecticut, where he graduated with honors as a University Scholar.
As President/COO of Epirus Biopharmaceuticals (2012-2016), Michael managed a portfolio of biosimilar monoclonal antibodies through development and commercial stages with global partners. Previously, he led R&D at Percivia, a J&J/DSM joint venture, and BioAssets Development, which was acquired by Cephalon for $120M. At Therion Biologics, he spearheaded the development of PROSTVAC, a prostate cancer immunotherapeutic vaccine later licensed by Bristol-Myers Squibb for $975M, while also managing the design and construction of a cGMP manufacturing facility in Cambridge.
Michael began his career as President and CSO at Mason Laboratory, a Genzyme Transgenics subsidiary, where he served as Principal Investigator on a $7M NIAID AIDS vaccine contract. He trained in comparative pathology at Harvard Medical School after earning his DVM from Purdue University and his PhD in Pathology from the University of Connecticut. He also holds a BS in Biology from the University of Connecticut, where he graduated with honors as a University Scholar.